Market Overview

Aramchol's Failed Past Isn't Its Future; Galmed Gets An Upgrade

Share:
Aramchol's Failed Past Isn't Its Future; Galmed Gets An Upgrade

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) lost a bull in February on Aramchol’s failed ARRIVE study for HIV-related fatty liver disease.

However, the drug is now generating optimism for distinct indications.

The Analyst

Maxim Group analyst Jason McCarthy upgraded Galmed to Buy and introduced a $14 price target.

The Thesis

By McCarthy’s estimates, Galmed’s Phase 2b data for Non-Alcoholic Steato-Hepatitis will catalyze the stock’s next inflection point.

“Our views may be considered ‘aggressive,’ but we don’t see the ARRIVE study results as a reliable predictor of the outcome of ARREST,” the analyst wrote in a note. “When we consider ARREST on its own, based on the factors above, we believe the risk/reward is favorable.”

The drug’s ARREST study is distinct from ARRIVE in indication, disease pathology, trial size and time and is not considered indicative of the candidate’s general prospects.

“The focus, in our view, should remain on the design of ARREST in NASH, based on positive data from a prior study, trial size and endpoints which we believe, at the current valuation, points to a favorable risk/reward profile,” McCarthy wrote.

ARREST data will be released in the second quarter, and McCarthy expects approval of Aramchol in 2022.

Price Action

Galmed spiked 15 percent in pre-market trading, but waned to trade up about 5.3 percent around $6.52 at time of publication.

Related Links:

Allergan Considering All Strategic Options 'With A Sense Of Urgency'

Height Casts 65% Odds That Congress Rolls Back Pharma Discounts

Latest Ratings for GLMD

DateFirmActionFromTo
Jul 2019Initiates Coverage OnBuy
Dec 2018Initiates Coverage OnBuy
Jul 2018Initiates Coverage OnOutperform

View More Analyst Ratings for GLMD
View the Latest Analyst Ratings

Posted-In: Jason McCarthy Maxim GroupAnalyst Color Upgrades Price Target Analyst Ratings Best of Benzinga

 

Related Articles (GLMD)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Goldman Sachs Gets Constructive On Insurance Brokers

A Convenient Way To Tap ETF Industry Growth